Personalized anticancer therapy
|
|
- Peter Cunningham
- 8 years ago
- Views:
Transcription
1 July 2015 Personalized anticancer therapy Israel R&D : Caesarea Business Park, P.O 4463 Caesarea Israel. U.S Office: #3 Bethesda Metro Center Suite 700 Bethesda, MD.
2 Company overview Cannabics Pharmaceuticals Inc. is engaged in the development and commercialization of personalized anticancer Cannabis based medicine. Cannabics focuses on the personalization of natural anticancer therapy. Utilizing throughput technology, we screen antitumor effects on biopsies treated with natural compounds. Since cannabis is known for its antitumor properties and has a great variance of active compounds, this in-vitro diagnostics process points out specific cannabis extracts with the potential of serving not only as a palliative treatment but also as an anticancer therapy. This technology enables the entourage of active ingredients found in diverse strains of cannabis to be harnessed in the fight against the diversity and sustainability of tumors. Personalized anticancer medicine There is a large cumulative and rapidly growing body of scientific data, which clearly indicates that cannabinoids specifically inhibit cancer cell growth and promote cancer cell death through apoptosis. We have developed an automated high-throughput method for the screening of different types of cancer cells or biopsies treated with a multitude of cannabis extracts. These natural extracts could also be tested in conjunction with approved synthetic drugs for patients that undergo chemotherapy for the most personally tailored therapy. This multilayer method is producing a large-scale database that will capture the knowledge gained on to the unique effects of different combinations of cannabinoid compounds on diverse malignancies. Coextensive with the development of the automated high-throughput 2
3 system, we are also developing proprietary and novel compounds targeted on diverse types of tumors. The advantages of Natural personalized Therapy Bio versatility- most drugs in the market are based on one active molecule, which has a well-established effect on the biology of the patient but usually, has harsh side effects for the same reason. It is more likely to assume that a large variety of molecules would treat a highly varied disease as cancer with more efficacy. Personalized Medicine -PM is treating the individual rather than groups of people. There are over 200 different known cancers and the genetic divergence among humans makes it nearly impossible to find one remedy for a group of people. PM is aiming to create a therapy for the biology of an individual by using personal biological data. Natural product- all natural compounds derived from the cannabis plant are well known for their non-toxic nature while standard chemotherapy is considered highly toxic with harsh side effects and in some cases cancerous itself. Cannabics SR As means of cannabis administration, Cannabics has developed a patent pending extended release formulation, distributed in Colorado as WannaCaps XR and studied as a palliative treatment for cancer patients in a renowned medical center in Israel. 3
4 A patent pending extended release cannabis capsule The Company s marketed product is Cannabics SR, an extended release oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR 10mg delivers a steady level of beneficial effects for 6-8 hours. The once to twice per-day oral dosing regimen offered by Cannabics SR allows patients a more consistent beneficial effect without the dizziness and dissociation commonly found with immediate release administration methods or the inconvenience of frequent re-dosing. It also avoids the medical complications associated with smoking cannabis and the uneven dosage frequently encountered in other edibles. Cannabics SR Clinical Research and Development On July 2014, the Company filed a non-provisional patent application with the U.S. Patent & Trademark Office and an international patent application with the Patent Cooperation Treaty division of the Israeli Patent Office, each covering the proprietary technology underlying Cannabics SR. A clinical study in underway in the Oncology Department of the Rambam Medical Center will examine the effectiveness of Cannabics SR in reducing nausea and improving the appetite of oncology patients, as 4
5 well as general improvement in quality of life and reduction of depression. We expect the first results to be available in September You can find this study under Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients or from the NIH Clinical Trials website: - contacts You can also see a more in-depth review at the (US) National Cancer Institute s website: althprofessional&protocolsearchid= We believe that clinical proof of safety and efficacy is of very high importance for the medical community and particularly to prescribing physicians. We anticipate that successful completion of our upcoming clinical studies with the Cannabics SR capsules will further legitimize the use of the capsules in the eyes of the medical community and will facilitate market penetration of Cannabics SR through coverage in publications by key opinion leaders in palliative oncology. Cannabis SR in the U.S. market In December 2014, the Company and Mountain High Products LLC, a Colorado corporation based in Boulder, Colorado, executed a Letter of Engagement contemplating the grant of a license to Mountain High for the exclusive production and distribution of Cannabics SR technology in the USA under the label Wanacaps XR. 5
6 Wanacaps XR Three versions of Wanacaps XR are available in Colorado: High THC Capsules 10 mg of THC, 1 mg of CBD. THC/CBD Balanced Capsules --10 mg of THC and 10 mg of CBD. High CBD Capsules 10 mg of CBD, 1 mg of THC. In The news: 6
7 The Board Dr. Eyal Ballan - Co-founder and CTO Dr. Eyal Ballan is a co-founder of Cannabics Pharmaceuticals and serves as CTO. Dr. Ballan holds a Ph.D. in neurophysiology, EEG Brain wave analysis and attention. After his Ph.D. he was an entrepreneur in the field of biofeedback and developed a resonating neuro-feedback system. Dr. Ballan holds a M.Sc. in cancer research and was part of the research team who developed Salirasib (Treatment for Non-Small Cell Lung Cancer). His expertise is in molecular biology, cell cultures and genomics and neurophysiology. Mr. Itamar Borochov - Co-founder and CEO Mr. Borochov is an environmentalist with vast experience as an entrepreneur in the fields of organic agriculture and medical cannabis. For more than 15 years prior to his involvement with medical cannabis, Mr. Borochov was a real estate entrepreneur. Mr. Shay Avraham Sarid - Co-founder Mr. Sarid is a co-founder of Cannabics Inc. and he is also the founder of Seach, one of the oldest and largest medical Cannabis farms in Israel. Seach is an official supplier of medical grade Cannabis to the Israeli Ministry of Health and specifically licensed to grow and distribute medical cannabis to authorized patients. Shay is the recent Chairman of the Israeli Medical Cannabis Growers Council. 7
8 Mr. Dov Weinberg Chief Financial Officer Mr. Weinberg has over 30 years of broad experience in corporate finance including more than 13 years in the Bio-tech, life science and medical device industries. He has been in executive positions for several US public companies including their world-wide subsidiaries. Mr. Weinberg is a Certified Public Accountant since 1979 and holds an MBA from Bar Ilan University (1984) and a B.A. in Economics and Accounting from Tel Aviv University (1977). Mr. David E. Price, Esq. Mr. David E. Price is our Secretary and corporate attorney, a native Washingtonian & has lived both in America and Israel & is fluent in several languages. David brings a dynamic and varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as a Congressional Aide in the US Congress, and General Counsel to consultants at the World Bank as well as the IDB, EX-IM and IMF in Washington, DC. He left a large international firm to create his own niche solo practice in mergers & acquisitions and brings years of knowledge both general and specific in the international business and corporate. Board of Advisors Dr. Sigalit Ariely-Portnoy Senior advisor in the field of regulation, validation and quality, Dr. Sigalit Ariely-Portnoy has over 17 years experience in the pharmaceutical industry. During this time, she has managed pharmaceutical and chemical plants at Taro pharmaceutical industries as Operation Group Vice president and in Teva Pharmaceutical industries. she managed Teva's largest plant worldwide. 8
9 During her career, she led more than 50 inspections by the US FDA, EMEA, Israeli MOH, and others. Dr. Ariely-Portnoy received her B.Sc., M.Sc., and D.Sc. from the Technion Institute of Technology in Haifa, Israel, in the fields of Chemical Engineering and Biomedical Engineering. Mr. Isaac Abravanel Senior advisor in the field of operational and strategic planning, Mr. Isaac Abravanel joined Teva Pharmaceutical Industries Ltd as its Corporate Vice President of Human Resources in During 2009, Mr. Abravanel was appointed as Teva s Chief Integration Officer, and as such led the postmerger integration processes of Teva s large acquisitions in recent years. In 2013 Mr. Abravanel was appointed as Group Executive Vice President of Teva Corporate in Israel and Global Community Alliances of Teva Pharmaceutical Industries Ltd. Mr. Abravanel holds a B.A and an M.A. in Political Science from Haifa University and is a Graduate of the National Security College. 9
Research: Medical Cannabis
Research: Medical Cannabis Background The hemp plant Cannabis sativa (cannabis) is commonly known as marijuana and can be used as a therapy to alleviate symptoms such as pain and fatigue caused by chronic
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationMEDICINAL CANNABIS IN ISRAEL, 2015
MEDICINAL CANNABIS IN ISRAEL, 2015 Ilya Reznik M.D. Chief Physician, MaReNa Consulting Center, Israel Coordinator, Israel Forum/Association for Medical Cannabis Research and Treatment Board of Directors,
More informationOPKO Health to Acquire Bio-Reference Laboratories
OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition
More informationClinical and Therapeutic Cannabis Information. Written by Cannabis Training University (CTU) All rights reserved
Clinical and Therapeutic Cannabis Information Written by Cannabis Training University (CTU) All rights reserved Contents Introduction... 3 Chronic Pain... 6 Neuropathic Pain... 8 Movement Disorders...
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT. Building an. Oncology Franchise
ALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT Building an Oncology Franchise Allos is a product company that develops and commercializes small molecule oncology and cardiovascular drugs. Our lead product
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationHow To Combine The Two Companies Into A Single Company
Announcement no. 22/2007 To OMX The Nordic Exchange, Copenhagen, and the press Vedbæk, November 27, 2007 EXIQON TO ACQUIRE ONCOTECH INC AND ENTER THE MARKET FOR CANCER MOLECULAR DIAGNOSTICS IN 2008 Summary:
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationJanssen Research & Development 3210 Merryfield Row San Diego, CA 92121
NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks
More informationIN THE SENATE OF THE UNITED STATES
II D CONGRESS 1ST SESSION S. 1 To amend title XVIII of the Social Security Act to provide for uniform coverage of anticancer drugs under the medicare program, and for other purposes. IN THE SENATE OF THE
More informationNational Framework for Excellence in
National Framework for Excellence in Lung Cancer Screening and Continuum of Care declaration of purpose Rights and Expectations THE RIGHTS OF THE PEOPLE Lung cancer kills more Americans than the next four
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationWhat is Glioblastoma? How is GBM classified according to the WHO Grading System? What risk factors pertain to GBM?
GBM (English) What is Glioblastoma? Glioblastoma or glioblastoma multiforme is one of the most common brain tumors accounting for approximately 12 to 15 percent of all brain tumors. The name of the tumor
More informationAnnette E. Fleckenstein, M.S., Ph.D.
Annette E. Fleckenstein, M.S., Ph.D. Professor of Dentistry Deputy Director, Utah Addiction Center University of Utah http://healthsciences.utah.edu/utahaddictioncenter/ fleckenstein@hsc.utah.edu Marijuana
More informationProfile of Biomedical Research and Biotechnology Commercialization. Washington-Baltimore Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization Washington-Baltimore Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Washington-Baltimore The Washington,
More informationThe Biotech Business Life Cycle. The Lawyer s Role as Counselor and Advisor
The Biotech Business Life Cycle and The Lawyer s Role as Counselor and Advisor ASU February 15, 2010 1 BIOTECH BUSINESS CYCLE AN INTERDISCIPLINARY APPROACH TO LEGAL REPRESENTATION Intellectual Property
More informationIndividualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
More informationMediSapiens Ltd. Bio-IT solutions for improving cancer patient care. Because data is not knowledge. 19th of March 2015
19th of March 2015 MediSapiens Ltd Because data is not knowledge Bio-IT solutions for improving cancer patient care Sami Kilpinen, Ph.D Co-founder, CEO MediSapiens Ltd Copyright 2015 MediSapiens Ltd. All
More informationHouston Cancer Institute
Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support
More informationHow To Understand And Understand Biosimilars
Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationFor personal use only
6 July 2015 KEY ADVANCEMENT TOWARDS COMMENCEMENT OF PHASE 1 CLINICAL STUDY OF ORAL FORMULATIONS Highlights PhytoTech Medical has submitted key documents to the Institutional Review Board (IRB or Helsinki
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationGroundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
More informationTRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY
TRENDS SHAPING THE FUTURE OF PERSONALIZED CARE AND THE DELIVERY OF SPECIALTY PHARMACY Key Takeaways from the June 18, 2013 Regional Symposium Nashville, Tennessee THE SYMPOSIUM Trends Shaping the Future
More informationHow Can Institutions Foster OMICS Research While Protecting Patients?
IOM Workshop on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials How Can Institutions Foster OMICS Research While Protecting Patients? E. Albert Reece, MD, PhD, MBA Vice
More informationMasters Learning mode (Форма обучения)
Program Title (Название программы): Pharmacology Degree (Степень) Masters Learning mode (Форма обучения) Full-time and part-time Duration of study (Продолжительность программы) 2 years (4 years part time)
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationBDO-I2I India Business Consulting. Company Profile
BDO-I2I India Business Consulting Company Profile Page 2 BDO-I2I Overview BDO-I2I is Israel s leading India focused business consulting firm Joint venture between BDO Consulting Group and I2I Ventures
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
More informationPATENTS. Pharmaceutical Product Patenting Strategies
PATENTS Pharmaceutical Product Patenting Strategies 1. What is a product patent? A product patent is a patent giving protection to a product as such, e.g. as an apparatus, a device or a chemical compound.
More informationPARTNER SEARCH FORM. MedAdvizor.org. Type of Company x HT R&D Research Institute University Other. Year Established 2013 No.
1. Company Profile 1.1 General Profile Full Name of Company MedAdvizor.org Registration # 514079573 Prior name of Company KDE Business Control Systems Ltd Type of Company x HT R&D Research Institute University
More informationTwo-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis
Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple
More informationLoma Linda University and Siemens PETNET Solutions, Inc.
Loma Linda University and Siemens PETNET Solutions, Inc. announce operational state-of-theart PET production and research facility to advance molecular imaging FOR IMMEDIATE RELEASE CONTACT: Susan Onuma
More informationUNCLASSIFIED STATEMENT BY
UNCLASSIFIED FINAL STATEMENT BY CAROLYN J.M. BEST, PhD PROGRAM MANAGER OF THE PROSTATE CANCER RESEARCH PROGRAM OF THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OF THE UNITED STATES ARMY MEDICAL
More informationMARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016
MARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016 EDUCATIONAL OBJECTIVES Describe the mechanism of action and effects of
More informationCancer Treatment Moringa Oleifera for Cancer Prevention or Treatment
Cancer Treatment Moringa Oleifera for Cancer Prevention or Treatment As we learn more about cancer, we are empowered to use more of the tools which nature has created for us to help battle this terrible
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationJUST THE FACTS: MARIJUANA AND MEDICINE
Marijuana and Your Health: Just The Facts Part II JUST THE FACTS: MARIJUANA AND MEDICINE Is marijuana medicine? In short, smoked crude marijuana is not medicine. However, marijuana does have medicinal
More informationBreakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction
Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationTechnology funding opportunities at the National Cancer Institute
Technology funding opportunities at the National Cancer Institute Through the Cancer Diagnosis Program http://cancerdiagnosis.nci.nih.gov/index.html Avraham Rasooly Ph.D. National Cancer Institute, Cancer
More informationAnnual Report on Form 20-F
Annual Report on Form 20-F 2 Teva at a Glance Founded in 1901 by three young pharmacists, today Teva Pharmaceutical Industries Ltd. is a leader in the global pharmaceutical industry, providing medicines
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationMULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
More informationNew York Bio Conference 2016. Mark J. Alles Chief Executive Officer
New York Bio Conference 2016 Mark J. Alles Chief Executive Officer Great Progress AGE 72 World Life Expectancy 2005-2014* 17 new drugs for rare diseases 71.5 71 Two new MS drugs First drug to target root
More informationMaster of Science in Vision Science and Investigative Ophthalmology MVSIO
Master of Science in Vision Science and Investigative Ophthalmology MVSIO Global Leadership in Eye Care, Vision Research and Ophthalmology Education Bascom Palmer Eye Institute is pleased to introduce
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationNational Cancer Institute
Technology Transfer Center National Cancer Institute NCI Shady Grove 9609 Medical Center Dr. Room 1E-530, MSC 9702 Bethesda, MD 20892-9702 Telephone: 240-276-5530 Fax: 240-276-5504 Technology Transfer
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationDrug Discovery in China
Drug Discovery in China Media Visit to Roche in China Shanghai 30 October 2005 Li Chen, Ph. D. Head of Research, Chief Scientific Officer Roche R&D Center (China) Ltd. Research Business Model in China
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationThere are 2 types of clinical trials that are of interest to the. The Clinical Trials Network of the Society of Nuclear Medicine
The Clinical Trials Network of the Society of Nuclear Medicine Michael M. Graham, PhD, MD The Clinical Trials Network of the Society of Nuclear Medicine was formed to provide quality assurance of both
More informationIncreasing Patient Access through Oral Parity Legislation
Increasing Patient Access through Oral Parity Legislation The Leukemia & Lymphoma Society A powerhouse among nonprofits searching for cancer cures Our Mission; Cure leukemia, lymphoma, Hodgkin s disease
More informationINVITATION LETTER ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC.
INVITATION LETTER COUNTRY: RWANDA SOURCE OF FUNDS: ORDINARY BUDGET ASSIGNMENT TITLE: INDIVIDUAL CONSULTANCY SERVICES RELATED TO THE TRAINING ON ADVANCED GCP TRAINING FOR RBC/MRC. REFERENCE NUMBER: 034/CS/ICS/2014-2015/RBC-MRC
More informationBS in Pharmaceutical Science (BSPS) degree program University of Rhode Island
To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,
More informationMaster of Bioethics Degree Program
Master of Bioethics Degree Program Offered as a full-time (one-year) or part-time (two-year) course of study This degree program, offered by the Center for Bioethics at Harvard Medical School, offers education,
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationStrategic Consulting Services
Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief
More informationwww.iproteos.com Corporate Presentation November, 2013
www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)
More informationBachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationSPHERIX INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationMalignant Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2888197/ Malignant Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Mesothelioma - Pipeline Review, H2 2014 Summary
More informationCompany Profile // May 2012
Company Profile // May 2012 1 Disclaimer This presentation has been prepared for the group of companies held by Clal Biotechnology Industries Ltd. (CBI or the Group ) and is provided to you solely for
More informationProfile of Biomedical Research and Biotechnology Commercialization. San Francisco Oakland San Jose Consolidated Metropolitan Statistical Area
Profile of Biomedical Research and Biotechnology Commercialization San Oakland San Jose Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in San The San Bay area is in many
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More information209: Using Competitive Intelligence to Drive your IP Portfolio
ACC s 2013 Annual Meeting Monday, October 28 11:00 AM - 12:30 PM 209: Using Competitive Intelligence to Drive your IP Portfolio Christine Collard Partner Borden Ladner Gervais LLP Ywe Looper Director,
More informationA Guide to Medical Marijuana
A Guide to Medical Marijuana Thousands of Marijuana Medicines Why Can Doctors Prescribe Only Two? By Sue Rusche President and CEO, National Families in Action April, 2014 National Families in Action has
More informationBioethics Education in Professional Science Master s Programs at California State University Channel Islands
ETHICS AND THE PSM Bioethics Education in Professional Science Master s Programs at California State University Channel Islands Ching-Hua Wang, M.D., Ph.D., Director of MS Biotechnology and Bioinformatics
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationTREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE
Providing the best in cancer care for Veterans TREATING LUNG CANCER AT VA PITTSBURGH HEALTHCARE SYSTEM A HERO S GUIDE VA Pittsburgh s state-of-the-art TomoTherapy machine, which delivers radiation to patients.
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationManufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH
Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your
More informationHISTORY OF ESCOZINE FOR PETS
HISTORY OF ESCOZINE FOR PETS Table of Contents I. Escozine For Pets verses Escozul / Vidatox... 2 II. Patent... 2 III. Labiofam... 2 IV. Location / Natural Habitat of the Caribbean Blue Scorpion... 3 V.
More informationAposense Enhancing Drug Effects
Aposense Enhancing Drug Effects Miri Ben-Ami, M.D. CEO IATI Biomed June 2013 Aposense Proprietary FORWARD LOOKING STATEMENTS The following slides contain forward-looking statements that include, but are
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationContents. Page 1 of 21
Programme-specific Section of the Curriculum for the MSc Programme in Biochemistry at the Faculty of Science, University of Copenhagen 2009 (Rev. 2015) Contents... 1 1 Title, affiliation and language...
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationA Career in Pediatric Hematology-Oncology? Think About It...
A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationThe Department of Education. in Science and Technology
The Department of Education in Science and Technology Graduate Studies M.Sc. and Ph.D. Programs January 2013 Table of Contents 1. Overview: M.Sc. and Ph.D. Graduate Studies programs in Science and Technology
More informationUnderstanding. Brain Tumors. Jana, diagnosed in 1999, with her husband, Paul.
Understanding Brain Tumors Jana, diagnosed in 1999, with her husband, Paul. What Is a Brain Tumor? A brain tumor, like other tumors, is a collection of cells that multiply at a rapid rate. The tumor may
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationClinical Trials: The Crux of Cancer Innovation
Clinical Trials: The Crux of Cancer Innovation Even as medical science is transforming cancer care, major deficiencies in the way cancer clinical trials are designed, carried out, regulated and funded
More informationTOP 10 TRENDS IN HEALTHCARE, MEDICAL. HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer
TOP 10 TRENDS IN HEALTHCARE, MEDICAL AND PHARMACEUTICAL INDUSTRY HJ ABDUL AZIZ ABDUL RAHMAN Chief Executive Officer KPJSeremban Specialist Hospital KPJ SEREMBAN SPECIALIST HOSPITAL Presented by : Hj Abd
More information